Rx-Strength Pepcid Could Join Prilosec OTC In Consumer Market
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson/Merck is preparing to introduce a prescription strength version of Pepcid (famotidine) for over-the-counter sale
You may also be interested in...
Maximum Strength Pepcid AC Approval Calls For Postmarketing Study
Johnson & Johnson/Merck is required to submit a protocol by late March 2004 for a postmarket study on Pepcid AC (famotidine) (10 mg) and new Maximum Strength Pepcid AC (20 mg), following FDA approval of the latter Sept. 24
Maximum Strength Pepcid AC Approval Calls For Postmarketing Study
Johnson & Johnson/Merck is required to submit a protocol by late March 2004 for a postmarket study on Pepcid AC (famotidine) (10 mg) and new Maximum Strength Pepcid AC (20 mg), following FDA approval of the latter Sept. 24
Maximum Strength Pepcid AC Approval Calls For Postmarketing Study
Johnson & Johnson/Merck is required to submit a protocol by late March 2004 for a postmarket study on Pepcid AC (famotidine) (10 mg) and new Maximum Strength Pepcid AC (20 mg), following FDA approval of the latter Sept. 24